Morgan Stanley’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $331M | Sell |
|
|||||
|
2025
Q2 | $251M | Buy |
|
|||||
|
2025
Q1 | $173M | Sell |
|
|||||
|
2024
Q4 | $171M | Buy |
|
|||||
|
2024
Q3 | $170M | Sell |
|
|||||
|
2024
Q2 | $180M | Buy |
|
|||||
|
2024
Q1 | $101M | Sell |
|
|||||
|
2023
Q4 | $309M | Buy |
|
|||||
|
2023
Q3 | $214M | Sell |
|
|||||
|
2023
Q2 | $357M | Buy |
|
|||||
|
2023
Q1 | $247M | Sell |
|
|||||
|
2022
Q4 | $330M | Sell |
|
|||||
|
2022
Q3 | $300M | Buy |
|
|||||
|
2022
Q2 | $165M | Buy |
|
|||||
|
2022
Q1 | $139M | Sell |
|
|||||
|
2021
Q4 | $181M | Sell |
|
|||||
|
2021
Q3 | $355M | Sell |
|
|||||
|
2021
Q2 | $319M | Buy |
|
|||||
|
2021
Q1 | $252M | Buy |
|
|||||
|
2020
Q4 | $220M | Buy |
|
|||||
|
2020
Q3 | $221M | Buy |
|
|||||
|
2020
Q2 | $224M | Buy |
|
|||||
|
2020
Q1 | $151M | Sell |
|
|||||
|
2019
Q4 | $177M | Buy |
|
|||||
|
2019
Q3 | $110M | Buy |
|
|||||
|
2019
Q2 | $97M | Buy |
|
|||||
|
2019
Q1 | $114M | Buy |
|
|||||
|
2018
Q4 | $86.2M | Sell |
|
|||||
|
2018
Q3 | $108M | Sell |
|
|||||
|
2018
Q2 | $124M | Sell |
|
|||||
|
2018
Q1 | $150M | Buy |
|
|||||
|
2017
Q4 | $148M | Buy |
|
|||||
|
2017
Q3 | $115M | Sell |
|
|||||
|
2017
Q2 | $81.2M | Buy |
|
|||||
|
2017
Q1 | $36M | Sell |
|
|||||
|
2016
Q4 | $30.4M | Sell |
|
|||||
|
2016
Q3 | $57M | Sell |
|
|||||
|
2016
Q2 | $48.6M | Sell |
|
|||||
|
2016
Q1 | $67.7M | Sell |
|
|||||
|
2015
Q4 | $103M | Sell |
|
|||||
|
2015
Q3 | $97.4M | Sell |
|
|||||
|
2015
Q2 | $156M | Sell |
|
|||||
|
2015
Q1 | $146M | Buy |
|
|||||
|
2014
Q4 | $133M | Buy |
|
|||||
|
2014
Q3 | $67.3M | Sell |
|
|||||
|
2014
Q2 | $54.8M | Buy |
|
|||||
|
2014
Q1 | $49.6M | Sell |
|
|||||
|
2013
Q4 | $47.7M | Buy |
|
|||||
|
2013
Q3 | $12.2M | Buy |
|
|||||
|
2013
Q2 | $1.65M | Buy |
|